Related Experiment Video
Updated: May 8, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Immune therapy for kidney cancer: a second dawn?
David F McDermott1, Michael B Atkins
1Biologic Therapy Program, Beth Israel Deaconess Medical Center; Department of Medicine, Harvard Medical School, Boston, MA, USA. dmcdermo@bidmc.harvard.edu
Seminars in Oncology
|August 27, 2013
Summary
New immunotherapies activate anti-tumor immune responses within the tumor, offering durable responses with less systemic toxicity for metastatic renal cell carcinoma (RCC). Research is exploring predictive biomarkers for immunotherapy effectiveness.
Area of Science:
- Oncology
- Immunology
- Medical Science
Background:
- Metastatic renal cell carcinoma (RCC) treatment historically relied on immune system agents.
- Targeted therapies have largely replaced traditional immune agents in RCC management.
- Recent advancements focus on modulating anti-tumor immune responses within the tumor microenvironment.
Purpose of the Study:
- To explore novel immunotherapeutic approaches for metastatic renal cell carcinoma (RCC).
- To investigate agents that activate localized anti-tumor immune responses, minimizing systemic toxicity.
- To identify potential predictive biomarkers for immunotherapy response in RCC.
Main Methods:
- Review of current research on immune system agents in RCC.
- Analysis of novel therapeutic strategies focusing on in-situ immune activation.
- Exploration of tumor immunology insights for biomarker development.
Main Results:
- Development of agents activating immune responses primarily within the tumor.
- Potential for durable tumor response with reduced systemic toxicity.
- Advancement in understanding tumor immunology for biomarker discovery.
Conclusions:
- Novel immunotherapies show promise for treating metastatic renal cell carcinoma (RCC).
- Targeting immune checkpoints represents a key area of clinical investigation in RCC.
- Further research into predictive biomarkers is crucial for optimizing immunotherapy in RCC.
Related Concept Videos
01:26Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:16Kidney Transplant III: Nursing Management
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:28Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...